NGM Biopharmaceuticals
Edit

NGM Biopharmaceuticals

http://www.ngmbio.com/
Last activity: 19.07.2024
Active
Categories: DevelopmentDrugEngineeringHealthTechHumanInterestMarketMedTechPlatformResearch
We are a clinical stage biopharmaceutical company advancing a robust pipeline of drug candidates to address a spectrum of large, unmet medical needs. We are focused on harnessing powerful, untapped biology underlying major diseases to develop transformative therapeutics for patients.

Our initial R&D focus has been to develop a portfolio of high-impact therapeutics for the underserved patient populations who suffer from cardio-metabolic and liver diseases. We believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of other disease areas as well, such as cancer.

NGM Bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. As we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. Coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles.

All of NGM Bio’s clinical candidates are first-in-class therapies and several are modulating targets or pathways that were first identified by NGM Bio.
Followers
367
Mentions
51
Location: United States, California, South San Francisco
Employees: 201-500
Total raised: $101M
Founded date: 2008

Investors 4

Funding Rounds 2

DateSeriesAmountInvestors
18.07.2013Series C$50M-
15.03.2010Series B$51M-

Mentions in press and media 51

DateTitleDescription
19.07.2024The Week’s 10 Biggest Funding Rounds: Cardurion Pharmaceuticals And Human Interest Nab Largest Raises5 Shares Email Facebook Twitter LinkedIn Want to keep track of the largest startup funding deals in 2024 with our curated list of $100 million-plus venture deals to U.S.-based companies? Check out The Crunchbase Megadeals Board. This is a w...
19.03.2024NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual MeetingSOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced th...
11.03.2024NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results-
11.03.2024NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results--Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab) with expected c...
26.02.2024NGM to go private as part of $135M buyout by VC firm Column GroupFollowing a year that saw a third of staff laid off and a sliding share price, NGM Bio has decided to go private as part of a $135 million buyout by VC firm The Column Group. A special committee of “independent and disinterested directors” ...
20.02.2024NGM Bio to Participate in the Cowen 44th Annual Health Care ConferenceSOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J....
25.05.2023NGM Bio to Participate in Upcoming Investor Conferences/EIN News/ -- SOUTH SAN FRANCISCO, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today ...
08.05.2023NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Bile Acid Ma...Aldafermin demonstrated statistically significant reductions in serum 7αC4 (a marker of bile acid synthesis) and fecal bile acids versus placebo in patients with idiopathic BAM with IBS-D Around 25-50% of patients with diarrhea-predominant ...
04.05.2023NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 DataPhase 2b ALPINE 4 trial met its primary endpoint, demonstrating a statistically significant improvement in Enhanced Liver Fibrosis (ELF) score at 48 weeks versus baseline in patients with compensated cirrhosis (F4) due to NASH treated with ...
25.03.2023Her doctor said her severe morning sickness was all in her head – but this scientist wanted to find the truthTaped above a tidy wooden desk in the corner of her bedroom, right at eye level, is a piece of paper that Marlena Fejzo has saved for 24 years. It’s a portrait of Dr Fejzo at age 31 during the worst ordeal of her life. Her face and body are...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In